TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31983605

Group type: EXPERIMENTAL
Intervention: Tamsulosin for one week before biopsy continuing for one week after biopsy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no alpha-blocker treatment)
Number of subjects: 112
Study: 29925127

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 30
Study: 27097977

Group type: EXPERIMENTAL
Intervention: ivacaftor
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Pulmonary exacerbations (PEs) requiring hospitalization
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: ppFEV1
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 161
Study: 25720546

Group type: EXPERIMENTAL
Intervention: Miconazole nitrate vaginal suppository 1,200 mg
Number of subjects: 577

Group type: COMPARATOR
Intervention: Oral fluconazole 150 mg
Number of subjects: 577
Study: 23259453

Group type: EXPERIMENTAL
Intervention: Adefovir 10 mg daily for 48 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21157043

Group type: EXPERIMENTAL
Intervention: 0.02 M alum mouthrinse
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Saturated saline rinse
Number of subjects: 3

Group type: COMPARATOR
Intervention: Distilled water (placebo) rinse
Number of subjects: 3
Study: 19001325

Group type: EXPERIMENTAL
Intervention: FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin)
Number of subjects: 1691

Group type: COMPARATOR
Intervention: IFL (irinotecan plus bolus fluorouracil and leucovorin)
Number of subjects: 1691

Group type: COMPARATOR
Intervention: IROX (bolus irinotecan/oxaliplatin)
Number of subjects: 1691
Study: 16611389

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (1 g ascorbic acid 2 hours pre- and for 14 days post-exercise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14662633

Group type: EXPERIMENTAL
Intervention: The COACH Program (coaching via telephone and mailings)
Number of subjects: 792

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: The COACH Program
Number of subjects: 792
Study: 10913806

Group type: EXPERIMENTAL
Intervention: Treatment with a beneficial effect on the nonfatal outcome
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment effect on mortality)
Number of subjects: 0
Study: 8853764

Group type: EXPERIMENTAL
Intervention: Ondansetron (5-HT3 antagonist)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 1479514

Group type: EXPERIMENTAL
Intervention: Vibro-acoustic stimulation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 21
Study: 6725789

Group type: EXPERIMENTAL
Intervention: Negatively ionized air
Number of subjects: 36

Group type: COMPARATOR
Intervention: Air-placebo condition
Number of subjects: 36
Study: 30204518

Group type: EXPERIMENTAL
Intervention: Hook Grip (HG)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Closed Grip
Number of subjects: 11
Study: 27551990

Group type: EXPERIMENTAL
Intervention: Active cycling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Passive cycling (placebo)
Number of subjects: 60
Study: 25678394

Group type: EXPERIMENTAL
Intervention: Immunoembolization with GM-CSF
Number of subjects: 52

Group type: COMPARATOR
Intervention: Bland embolization (BE)
Number of subjects: 52
Study: 24329816

Group type: EXPERIMENTAL
Intervention: Oscillation applicator
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hand application
Number of subjects: 20
Study: 22527628

Group type: EXPERIMENTAL
Intervention: Posterior fossa decompression (PFD) only in group Ia (12 cases)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Posterior fossa decompression (PFD) with fourth ventricular shunt in group Ib (14 cases)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Posterior fossa decompression (PFD) and syringosubarachnoid shunt in group Ic (6 cases)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Posterior fossa decompression (PFD) only in group II (14 cases)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Postoperative MRI results
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Recurrence of symptoms
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Syringosubarachnoid shunting
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fourth ventricular shunt in cases of syringomyelia
Number of subjects: 46
Study: 19262985

Group type: EXPERIMENTAL
Intervention: Prophylactic subfascial polypropylene mesh reinforcement of midline closure (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional method only (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 17461928

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg day(‐1))
Number of subjects: 20
Study: 15175199

Group type: COMPARATOR
Intervention: Frontal chest radiograph alone (Group 1)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Frontal and lateral chest radiographs (Group 2)
Number of subjects: 570
Study: 11201769

Group type: EXPERIMENTAL
Intervention: Comprehensive corporate wellness effort
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Workers' compensation and disability program interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coordinated program
Number of subjects: 0
Study: 9273008

Group type: EXPERIMENTAL
Intervention: Amidotrizoate (ionic contrast medium)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Iopromid (non-ionic contrast medium)
Number of subjects: 20
Study: 8108609

Group type: EXPERIMENTAL
Intervention: Small amplitude (SO) hypoxic stimulation (PET(O2) from 63.2 to 54.9 Torr) at 2 Torr above resting PET(CO2) (EC)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Large amplitude (LO) hypoxic stimulation (PET(O2) from 73.0 to 48.0 Torr) at 2 Torr above resting PET(CO2) (EC)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Small amplitude (SO) hypoxic stimulation (PET(O2) from 63.2 to 54.9 Torr) at 7 Torr above resting PET(CO2) (HC)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Large amplitude (LO) hypoxic stimulation (PET(O2) from 73.0 to 48.0 Torr) at 7 Torr above resting PET(CO2) (HC)
Number of subjects: 5
Study: 3802708

Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg
Number of subjects: 0
Study: 29087622

Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: Omnivorous diet
Number of subjects: 21
Study: 27169919

Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Cilostazol (‐)
Number of subjects: 51
Study: 25039997

Group type: EXPERIMENTAL
Intervention: Catheter-based radiofrequency renal denervation (RDN)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Drug treatment (Control)
Number of subjects: 39
Study: 22230154

Group type: EXPERIMENTAL
Intervention: Furosemide with matched hydration (FMH group, n = 87)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard intravenous isotonic saline hydration (control group, n = 83)
Number of subjects: 170
Study: 20819439

Group type: EXPERIMENTAL
Intervention: Gentamicin-absorbed collagen sponges placed on the sacral fascia, no oral post-operative antibiotics.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral antibiotics for 7 days post-operatively (Control group).
Number of subjects: 80
Study: 18487550

Group type: EXPERIMENTAL
Intervention: Mitoxantrone after docetaxel
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Docetaxel after mitoxantrone
Number of subjects: 232

Group type: COMPARATOR
Intervention: Crossover therapy
Number of subjects: 232
Study: 15953249

Group type: EXPERIMENTAL
Intervention: CO(2) laser irradiation at 8 J.cm(‐2)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CO(2) laser irradiation at 16 J.cm(‐2)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no laser irradiation)
Number of subjects: 33
Study: 14506488

Group type: EXPERIMENTAL
Intervention: 1.8 g CLA per day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 3.6 g CLA per day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 11204323

Group type: COMPARATOR
Intervention: ApoE genotype determination
Number of subjects: 45

Group type: COMPARATOR
Intervention: Tau protein level measurement in cerebro-spinal fluid (CSF)
Number of subjects: 45
Study: 8836932

Group type: EXPERIMENTAL
Intervention: Combination therapy (L-DOPA/benserazide + bromocriptine, nearly 40% replacement)
Number of subjects: 674

Group type: COMPARATOR
Intervention: Levodopa monotherapy
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Combination therapy (L-DOPA/benserazide + bromocriptine)
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Combination therapy (L-DOPA/benserazide + bromocriptine) with > 50% substitution
Number of subjects: 674
Study: 1998929

Group type: EXPERIMENTAL
Intervention: Geriatric day hospital treatment
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 113
Study: 6367345

Group type: EXPERIMENTAL
Intervention: Graded compression of the calf
Number of subjects: 62
Study: 31147367

Group type: EXPERIMENTAL
Intervention: Hyperuricaemia (HUA) defined as serum uric acid level >420 μmol/L in men and >360 μmol/L in women
Number of subjects: 11488

Group type: EXPERIMENTAL
Intervention: Hyperuricaemia (HUA)
Number of subjects: 11488

Group type: EXPERIMENTAL
Intervention: Serum uric acid level
Number of subjects: 11488

Group type: EXPERIMENTAL
Intervention: Age, living in urban areas, alcohol consumption, central obesity, elevated fasting plasma glucose level, elevated blood pressure, lower high-density lipoprotein cholesterol level, elevated triglycerides level
Number of subjects: 11488

Group type: EXPERIMENTAL
Intervention: Non-valvular atrial fibrillation (NVAF) diagnosed as per guidelines
Number of subjects: 11488
Study: 29274162

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) by Diode Laser GaAlAs (780nm), twice a week for six weeks
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Anesthetic infiltration of lidocaine 2% without vasoconstrictor, once a week for four weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Both treatments (LLLT and lidocaine infiltration)
Number of subjects: 66
Study: 27403531

Group type: EXPERIMENTAL
Intervention: Acupuncture catgut embedding therapy (ACET) with moxibustion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study: 25023152

Group type: EXPERIMENTAL
Intervention: 8-week early exercise and education programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 22554184

Group type: EXPERIMENTAL
Intervention: Individualized 12-week aerobic cycling training (TG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 18
Study: 20600185

Group type: EXPERIMENTAL
Intervention: Levodopa intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: No performance feedback
Number of subjects: 0
Study: 18047460

Group type: EXPERIMENTAL
Intervention: Trunk stabilisation exercises
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no exercises)
Number of subjects: 9
Study: 16131672

Group type: EXPERIMENTAL
Intervention: Blood salvage and reinfusion system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard allogeneic blood transfusion
Number of subjects: 60
Study: 11874215

Group type: COMPARATOR
Intervention: Clinician-guided behavior therapy
Number of subjects: 218

Group type: COMPARATOR
Intervention: Computer-guided behavior therapy
Number of subjects: 218

Group type: COMPARATOR
Intervention: Systematic relaxation
Number of subjects: 218
Study: 10208072

Group type: EXPERIMENTAL
Intervention: 10-minute training procedure based on the Carleton Skill Training Program
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Posttreatment suggestibility scores
Number of subjects: 98
Study: 8639349

Group type: EXPERIMENTAL
Intervention: Control of bias at entry (randomization)
Number of subjects: 91
Study: 2140743

Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg b.i.d.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Captopril (25 mg b.i.d.)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of ketanserin and captopril (20 mg b.i.d. and 25 mg b.i.d. respectively) for 45 days
Number of subjects: 40
Study: 6213682

Group type: EXPERIMENTAL
Intervention: Topical clindamycin (1% solution)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Oral tetracycline (250 mg)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 31877703

Group type: EXPERIMENTAL
Intervention: Street Food (SF)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Fast Foods (FF)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Artisanal Foods (AF)
Number of subjects: 189
Study: 29315665

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (sham RIPC)
Number of subjects: 44
Study: 27998863

Group type: EXPERIMENTAL
Intervention: Staged retrograde flexible ureteroscopic lithotripsy (FURS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Miniaturized percutaneous nephrolithotomy (m-PCNL)
Number of subjects: 70
Study: 25311693

Group type: EXPERIMENTAL
Intervention: Caregiver knowledge of diarrhea prevention practices
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Caregiver knowledge of food safety practices
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Health promotion interventions
Number of subjects: 952
Study: 21925813

Group type: EXPERIMENTAL
Intervention: Intrahepatic vein transfusion (IHV group)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Umbilical vein transfusion (PCI group)
Number of subjects: 19
Study: 19139160

Group type: EXPERIMENTAL
Intervention: Creative task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Being informed that creativity is culturally valued
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control topic
Number of subjects: 0
Study: 17924899

Group type: EXPERIMENTAL
Intervention: Disposable laryngeal tube (LT‐D)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Reusable laryngeal tube (LT‐R)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both LT‐D and LT‐R
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: LT‐D
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: LT‐R
Number of subjects: 100
Study: 16495752

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg to 100 mg daily for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Atenolol 50 mg to 100 mg daily for 6 months
Number of subjects: 30
Study: 12558613

Group type: EXPERIMENTAL
Intervention: 4% inclination
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 8% inclination
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 12% inclination
Number of subjects: 11

Group type: COMPARATOR
Intervention: Comparison of 12% inclination to 4% and 8%
Number of subjects: 11
Study: 10755337

Group type: EXPERIMENTAL
Intervention: Haemorrhoidectomy plus lateral internal sphincterotomy (LIS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Haemorrhoidectomy alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lateral internal sphincterotomy (LIS)
Number of subjects: 42
Study: 8638801

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 20
Study: 1355595

Group type: EXPERIMENTAL
Intervention: Electrophysiologically guided drug therapy
Number of subjects: 170

Group type: COMPARATOR
Intervention: Metoprolol therapy
Number of subjects: 170

Group type: COMPARATOR
Intervention: Metoprolol therapy (for noninducible arrhythmia)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Electrophysiologically guided drug therapy (for inducible arrhythmia that became noninducible)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Metoprolol therapy (for inducible arrhythmia that remained inducible)
Number of subjects: 170
Study: 6517245

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose droperidol (0.25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose droperidol (1.25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31968622

Group type: EXPERIMENTAL
Intervention: Infracyanine Green (IFCG)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Brilliant Blue G (BBG)
Number of subjects: 39
Study: 29329763

Group type: EXPERIMENTAL
Intervention: Varenicline (titrated to two 0.5 mg doses twice daily)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Varenicline (mITT analysis)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo (mITT analysis)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 27781970

Group type: EXPERIMENTAL
Intervention: Ultrasound simulator devices during critical care simulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25670823

Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam (1.5 g) plus metronidazole (500 mg) every 8 hours for 4-14 days
Number of subjects: 806

Group type: COMPARATOR
Intervention: Meropenem (1 g) every 8 hours for 4-14 days
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam plus metronidazole
Number of subjects: 806

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 806
Study: 23974194

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 1111

Group type: COMPARATOR
Intervention: Clodronate acid (CLO)
Number of subjects: 1111
Study: 20642906

Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 50
Study: 19025523

Group type: EXPERIMENTAL
Intervention: High-volume (170 ml) ropivacaine (0.2%) with epinephrine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 12
Study: 15707562

Group type: EXPERIMENTAL
Intervention: Nestorone (150 microg/day) and Ethinylestradiol (15 microg/day)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Nestorone (150 microg/day) and Ethinylestradiol (20 microg/day)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Nestorone (200 microg/day) and Ethinylestradiol (15 microg/day)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All doses combined
Number of subjects: 150
Study: 14616168

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg (R10) + amoxicillin 1,000 mg + clarithromycin 500 mg (AC)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg (R20) + amoxicillin 1,000 mg + clarithromycin 500 mg (AC)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Omeprazole 20 mg (O) + amoxicillin 1,000 mg + clarithromycin 500 mg (AC)
Number of subjects: 162
Study: 10440416

Group type: EXPERIMENTAL
Intervention: Clopidogrel 25 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clopidogrel 50 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clopidogrel 100 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clopidogrel (up to 75 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clopidogrel and Ticlopidine
Number of subjects: 24
Study: 8706295

Group type: EXPERIMENTAL
Intervention: Hexarelin (2 micrograms/kg i.v.)
Number of subjects: 14
Study: 1796819

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (Dermovate and another corticosteroid of differing potency) applied for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (another corticosteroid of differing potency) applied for 4 weeks
Number of subjects: 0
Study: 6689490

Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg daily for 7 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Antacid (Maalox, 105 ml daily for 7 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg daily for 7 days) in healthy volunteers
Number of subjects: 12
Study: 31342624

Group type: EXPERIMENTAL
Intervention: Abatacept 125 mg
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 31495601

Group type: EXPERIMENTAL
Intervention: Panel of 44 plasma proteins along with age and apolipoprotein E (APOE) ε4
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Mendelian randomization
Number of subjects: 881
Study: 29268794

Group type: EXPERIMENTAL
Intervention: List experiment method for measuring self-reported abortion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariable analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retrospective measurement of lifetime experience of abortion
Number of subjects: 0
Study: 26102262

Group type: EXPERIMENTAL
Intervention: 1RM Split Squat (1RM-SS)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 1RM Bilateral Squat (1RM-BLS)
Number of subjects: 14
Study: 23784898

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (5 g/day)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (10 g/day)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Subcutaneous recombinant GH (0 μg/kg/day)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant GH (3 μg/kg/day)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant GH (5 μg/kg/day)
Number of subjects: 112
Study: 21451442

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined intravitreal bevacizumab and triamcinolone (IVB/IVT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Macular laser photocoagulation
Number of subjects: 150
Study: 20225472

Group type: EXPERIMENTAL
Intervention: Fine grit oval tip + oval posts
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mtwo Post File drill + circular posts
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Medium grit oval tip + oval posts
Number of subjects: 15
Study: 17288644

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 102